22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › 4D Molecular Therapeutics, Inc. › 2024-2025

4D Molecular Therapeutics, Inc. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and 4D Molecular Therapeutics, Inc.’s Form 8-K, filed June 20, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Reported items
  • 145Asset managers, any item
  • 1,033Fund votes
  • June 17, 2025Meeting date

Results at a glance

Meeting of June 17, 2025: 5 items on 4D Molecular Therapeutics, Inc.’s Form 8-K, filed June 20, 2025: 2 approved · 3 passed (calculated).

Dissent

Notable dissent: 2 directors (15.4%, 11.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Ra Capital Management, L.P. (13F, 9.7%, as of September 30, 2026)

Explore 4D Molecular Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by 4D Molecular Therapeutics, Inc.

These tallies are 4D Molecular Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 20, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

4D Molecular Therapeutics, Inc. — official shareholder meeting results, meeting held June 17, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Jacob Chacko, M.D., MBA 28,579,453---- 3,691,9626,199,121 89%Passed (calculated)—
Elect Director: Susannah Gray, MBA 31,923,027---- 348,3886,199,121 99%Passed (calculated)—
Elect Director: Charles P. Theuer, M.D., Ph.D. 27,285,806---- 4,985,6096,199,121 85%Passed (calculated)—
2. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025 38,380,55281,4908,494 ---- 99.8%Approved—
3. On an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement 31,841,967394,00235,446 --6,199,121 99%Approved—

Source: 4D Molecular Therapeutics, Inc., Form 8-K, filed with the SEC on June 20, 2025 — read the filing on EDGAR.

How asset managers voted at the 4D Molecular Therapeutics, Inc. 2024-2025 meeting

145 asset managers disclosed a vote on at least one 4D Molecular Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of 4D Molecular Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Charles P. Theuer, M.D., Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD
FOR: 27,285,806WITHHELD: 4,985,609
Details: description as filed, official tally, votes by 44 asset managers

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Charles Theuer, M.D., Ph.D.

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Charles P. Theuer, M.D., Ph.D.”): 27,285,806 for, 4,985,609 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 8,401,540 for, 343,583 withheld.

FOR
FOR: 8,401,540WITHHOLD: 343,583
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until the” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,715,8540 00For
BlackRock2,349,0740 00For
Federated Hermes1,526,5620 00For
JANUS INVESTMENT FUND844,3780 00For
Charles Schwab284,8600 00For
Equitable82,2230 055,870Mixed
MERIDIAN FUND INC130,4350 00For
TIAA122,0850 00For
QUANTITATIVE MASTER SERIES LLC86,5360 00For
State Street67,4020 013For
American Century00 044,910Withhold
Invesco00 038,706Withhold
Lincoln Financial31,7000 04,816Mixed
Harbor ETF Trust30,5950 00For
ALPS ETF Trust00 028,311Withhold
Global X26,6800 00For
Northern Trust00 026,096Withhold
AIG/SunAmerica00 023,001Withhold
Brighthouse00 022,699Withhold
MASTER INVESTMENT PORTFOLIO19,0560 00For
John Hancock00 018,719Withhold
T. Rowe Price18,2250 00For
Pacific Life17,2850 00For
ETFis Series Trust I00 016,350Withhold
Voya00 014,500Withhold

Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).

Elect Director: Jacob Chacko, M.D., MBA

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 28,579,453WITHHELD: 3,691,962
Details: description as filed, official tally, votes by 44 asset managers

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Jacob Chacko, M.D., MBA

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Jacob Chacko, M.D., MBA”): 28,579,453 for, 3,691,962 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 8,466,342 for, 278,781 withheld.

FOR
FOR: 8,466,342WITHHOLD: 278,781
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until the” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,715,8540 00For
BlackRock2,349,0740 00For
Federated Hermes1,526,5620 00For
JANUS INVESTMENT FUND844,3780 00For
Charles Schwab284,8600 00For
Equitable82,2230 055,870Mixed
MERIDIAN FUND INC130,4350 00For
TIAA122,0850 00For
QUANTITATIVE MASTER SERIES LLC86,5360 00For
State Street67,4020 013For
American Century00 044,910Withhold
Invesco38,7060 00For
Lincoln Financial31,7000 04,816Mixed
Harbor ETF Trust30,5950 00For
ALPS ETF Trust00 028,311Withhold
Global X26,6800 00For
Northern Trust26,0960 00For
AIG/SunAmerica00 023,001Withhold
Brighthouse00 022,699Withhold
MASTER INVESTMENT PORTFOLIO19,0560 00For
John Hancock00 018,719Withhold
T. Rowe Price18,2250 00For
Pacific Life17,2850 00For
ETFis Series Trust I00 016,350Withhold
Voya00 014,500Withhold

Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).

Elect Director: Susannah Gray, MBA

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 2 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 31,923,027WITHHELD: 348,388
Details: description as filed, official tally, votes by 44 asset managers

Description as filed by funds: Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until their successors are elected: Susannah Gray, MBA

4D Molecular Therapeutics, Inc.’s own tally for this item (“Elect Director: Susannah Gray, MBA”): 31,923,027 for, 348,388 withheld, per its Form 8-K filed June 20, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 8,673,884 for, 71,239 withheld.

FOR
FOR: 8,673,884WITHHOLD: 71,239
Largest asset managers voting on “Election of three Class II directors to hold office until the 2028 Annual Meeting of Stockholders or until the” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,715,8540 00For
BlackRock2,349,0740 00For
Federated Hermes1,526,5620 00For
JANUS INVESTMENT FUND844,3780 00For
Charles Schwab284,8600 00For
Equitable82,2230 055,870Mixed
MERIDIAN FUND INC130,4350 00For
TIAA122,0850 00For
QUANTITATIVE MASTER SERIES LLC86,5360 00For
State Street67,4150 00For
American Century44,9100 00For
Invesco38,7060 00For
Lincoln Financial31,7000 04,816Mixed
Harbor ETF Trust30,5950 00For
ALPS ETF Trust28,3110 00For
Global X26,6800 00For
Northern Trust26,0960 00For
AIG/SunAmerica23,0010 00For
Brighthouse22,6990 00For
MASTER INVESTMENT PORTFOLIO19,0560 00For
John Hancock18,7190 00For
T. Rowe Price18,2250 00For
Pacific Life17,2850 00For
ETFis Series Trust I16,3500 00For
Voya14,5000 00For

Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).

On an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 10 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%
FOR: 31,841,967AGAINST: 394,002
Details: description as filed, official tally, votes by 145 asset managers

Description as filed by funds: Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("say-on-pay vote").

4D Molecular Therapeutics, Inc.’s own tally for this item (“3. On an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement”): 31,841,967 for, 394,002 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on an advisory, non-binding basis, the named executive officers' compensation as disclosed in the Proxy Statement.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 44 asset managers voting on “Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("s” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,715,8540 00For
BlackRock2,349,0740 00For
Federated Hermes1,526,5620 00For
JANUS INVESTMENT FUND844,3780 00For
Charles Schwab284,8600 00For
Equitable138,0930 00For
MERIDIAN FUND INC130,4350 00For
TIAA122,0850 00For
QUANTITATIVE MASTER SERIES LLC86,5360 00For
State Street67,4150 00For
American Century044,910 00Against
Invesco38,7060 00For
Lincoln Financial36,5160 00For
Harbor ETF Trust30,5950 00For
ALPS ETF Trust28,3110 00For
Global X26,6800 00For
Northern Trust26,0960 00For
AIG/SunAmerica23,0010 00For
Brighthouse22,6990 00For
MASTER INVESTMENT PORTFOLIO19,0560 00For
John Hancock18,7190 00For
T. Rowe Price18,2250 00For
Pacific Life17,2850 00For
ETFis Series Trust I16,3500 00For
Voya14,5000 00For

Fund voting reports, all 44 managers: 8,700,213 for, 44,910 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 113 asset managers voting on “Approval, on an advisory, non-binding basis, of the compensation of the Company's named executive officers ("s” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BVF INC/IL4,585,9830 00For
RA CAPITAL MANAGEMENT, L.P.4,399,9450 00For
Goldman Sachs2,149,6970 00For
Novo Holdings A/S2,000,0000 00For
BlackRock1,628,7970 00For
Janus Henderson1,624,3910 00For
Federated Hermes1,613,7280 00For
Two Sigma881,8310 00For
State Street777,8960 00For
MARSHALL WACE, LLP605,3420 00For
ArrowMark Colorado Holdings LLC442,0720 00For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND412,0000 00For
Northern Trust316,6920 00For
ARMISTICE CAPITAL, LLC300,0000 00For
Charles Schwab284,8600 00For
JPMorgan271,4070 00For
Decheng Capital LLC00 00--
Wellington180,0780 00For
MELLON INVESTMENTS Corp175,5610 00For
Nuveen150,3140 00For
Redmile Group, LLC141,1780 00For
Citadel135,8680 00For
Invesco116,8800 00For
Fidelity92,7460 00For
Point7267,7960 00For

Institutional-manager reports, all 113 managers: 24,082,377 for, 62,845 against, 96 not voted, 250,000 unknown, 18,353 1 year. Showing the 25 largest; every one is in the interactive database (link above).

Approval, on an advisory, non-binding basis, of the frequency of future advisory say-on-pay votes.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

99% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: votes by 141 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 44 asset managers voting on “Approval, on an advisory, non-binding basis, of the frequency of future advisory say-on-pay votes.” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
BlackRock00 00--
Federated Hermes00 00--
JANUS INVESTMENT FUND00 00--
Charles Schwab00 00--
Equitable00 00--
MERIDIAN FUND INC00 00--
TIAA00 00--
QUANTITATIVE MASTER SERIES LLC00 00--
State Street00 00--
American Century00 00--
Invesco00 00--
Lincoln Financial00 00--
Harbor ETF Trust00 00--
ALPS ETF Trust00 00--
Global X00 00--
Northern Trust00 00--
AIG/SunAmerica00 00--
Brighthouse00 00--
MASTER INVESTMENT PORTFOLIO00 00--
John Hancock00 00--
T. Rowe Price00 00--
Pacific Life00 00--
ETFis Series Trust I00 00--
Voya00 00--

Fund voting reports, all 44 managers: 8,734,636 1 year, 10,487 3 year. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 109 asset managers voting on “Approval, on an advisory, non-binding basis, of the frequency of future advisory say-on-pay votes.” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BVF INC/IL00 00--
RA CAPITAL MANAGEMENT, L.P.00 00--
Goldman Sachs00 00--
Novo Holdings A/S00 00--
BlackRock00 00--
Janus Henderson00 00--
Federated Hermes00 00--
Two Sigma00 00--
State Street00 00--
MARSHALL WACE, LLP00 00--
ArrowMark Colorado Holdings LLC00 00--
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND00 00--
Northern Trust00 00--
ARMISTICE CAPITAL, LLC00 00--
Charles Schwab00 00Not Voted
Wellington00 00--
MELLON INVESTMENTS Corp00 00--
Nuveen00 00--
Redmile Group, LLC00 00--
Citadel00 00--
Invesco00 00--
Fidelity00 00--
Point7200 00--
Maryland State Retirement & Pension System00 00--
Asset Management One Co., Ltd.00 00--

Institutional-manager reports, all 109 managers: 21,162 for, 303 against, 96 not voted, 23,829,214 1 year, 33,737 3 year. Showing the 25 largest; every one is in the interactive database (link above).

The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its…

Official resultAUDIT-RELATEDReported outcome: Approved

99.8% Approved · of votes cast

FOR 99.8%
FOR: 38,380,552AGAINST: 81,490

Prior year: 100.0% for (May 21, 2024 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 44 asset managers

Description as filed by funds: Ratification of the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.

4D Molecular Therapeutics, Inc.’s own tally for this item (“2. The selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025”): 38,380,552 for, 81,490 against — passed, per its Form 8-K filed June 20, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 44 asset managers below reported 8,743,871 for, 1,252 against.

FOR
FOR: 8,743,871AGAINST: 1,252
Largest asset managers voting on “Ratification of the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseC” at 4D Molecular Therapeutics, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard2,715,8540 00For
BlackRock2,349,0740 00For
Federated Hermes1,526,5620 00For
JANUS INVESTMENT FUND844,3780 00For
Charles Schwab284,8600 00For
Equitable138,0930 00For
MERIDIAN FUND INC130,4350 00For
TIAA122,0850 00For
QUANTITATIVE MASTER SERIES LLC86,5360 00For
State Street67,4141 00For
American Century44,9100 00For
Invesco38,7060 00For
Lincoln Financial36,5160 00For
Harbor ETF Trust30,5950 00For
ALPS ETF Trust28,3110 00For
Global X26,6800 00For
Northern Trust26,0960 00For
AIG/SunAmerica23,0010 00For
Brighthouse22,6990 00For
MASTER INVESTMENT PORTFOLIO19,0560 00For
John Hancock18,7190 00For
T. Rowe Price18,2250 00For
Pacific Life17,2850 00For
ETFis Series Trust I16,3500 00For
Voya14,5000 00For

Showing the 25 largest of 44 asset managers. All 44 are in the interactive database (link above).

Largest 4D Molecular Therapeutics, Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 49,778,127 shares outstanding at the time of that meeting.

Fund voting reports: top 4D Molecular Therapeutics, Inc. shareholders by shares voted on “Approval, on an advisory, non-binding basis, of the compensation of the Company's named…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 5.46%
2BlackRock 4.72%
3Federated Hermes 3.07%
4JANUS INVESTMENT FUND 1.70%
5Charles Schwab 0.57%
6Equitable 0.28%
7MERIDIAN FUND INC 0.26%
8TIAA 0.25%
9QUANTITATIVE MASTER SERIES LLC 0.17%
10State Street 0.14%
Institutional-manager reports: top 4D Molecular Therapeutics, Inc. shareholders by shares voted on “Approval, on an advisory, non-binding basis, of the compensation of the Company's named…”, 2024-2025
#Asset manager % of shares outstanding
1BVF INC/IL 9.21%
2RA CAPITAL MANAGEMENT, L.P. 8.84%
3Goldman Sachs 4.32%
4Novo Holdings A/S 4.02%
5BlackRock 3.27%
6Janus Henderson 3.26%
7Federated Hermes 3.24%
8Two Sigma 1.77%
9State Street 1.56%
10MARSHALL WACE, LLP 1.22%

Reported 4D Molecular Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

4D Molecular Therapeutics, Inc. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BVF PARTNERS L P/IL5,346,519 10.74%Schedule 13G, filed May 15, 2026
JANUS HENDERSON GROUP PLC5,247,151 10.54%Schedule 13G, filed April 7, 2026
RA Capital Management, L.P.4,564,867 9.17%Proxy statement (DEF 14A), proxy filed April 29, 2025
BlackRock4,547,152 9.13%Form 13F, quarter ended March 31, 2025
Goldman Sachs4,168,394 8.37%Form 13F, quarter ended March 31, 2025
Novo Holdings A/S3,650,737 7.33%Schedule 13G, filed February 17, 2026
Vanguard Group2,757,490 5.54%Form 13F, quarter ended March 31, 2025
Biotechnology Value Fund, L.P.2,670,642 5.37%Proxy statement (DEF 14A), proxy filed April 29, 2025
Morgan Stanley1,776,743 3.57%Form 13F, quarter ended March 31, 2025
David Kirn, M.D.1,659,153 3.33%Proxy statement (DEF 14A), proxy filed April 29, 2025

Percentages above are of 49,778,127 shares outstanding, as reported by 4D Molecular Therapeutics, Inc. on its Form 10-K dated February 23, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At 4D Molecular Therapeutics, Inc.'s shareholder meeting held June 17, 2025, in the 2024-2025 proxy season, 145 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,033 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory, non-binding basis, of the compensation of the Company's named… — 4D Molecular Therapeutics, Inc.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: 4D Molecular Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 20, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from 4D Molecular Therapeutics, Inc.’s 10-K dated February 23, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

4D Molecular Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “4D Molecular Therapeutics (FDMT) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/4d-molecular-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.